Title: Design of poly(DOPA)-based nanoparticle for Parkinson’s disease treatment with suppressing dyskinesia
Abstract: The major cause of Parkinson's disease (PD) is thought to be the loss of dopaminergic substantia nigra neurons and the formation of alpha-synuclein-containing Lewy bodies. Although dopamine supplementation is a vital therapy, it is not facile to cross the BBB. 3,4-Dihydroxyphenylalanine (L-DOPA), a dopamine precursor, is one of the main drugs to treat PD since L-DOPA can cross the BBB better than dopamine; however, there are strong demands to develop further effective drugs due to the short half-life and several adverse effects such as dyskinesia. In this study, we studied new drugs based on novel molecular self-assembling at overcoming the drawbacks of L-DOPA and creating safe and effective Parkinson's disease drugs, viz., a nanoparticle consists of poly(diacetyl L-DOPA) was designed, which improved the controlled release of L-DOPA and improved the therapeutic effects, suppressing its adverse effects.
Publication Year: 2021
Publication Date: 2021-10-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot